Evidence map›Paper›PMID 40008194›Full record

ReviewThe journal of physical chemistry. C, Nanomaterials and interfaces2025

Plasmonic Chirality Meets Reactivity: Challenges and Opportunities.

Charlène Brissaud, Swareena Jain, Olivier Henrotte, Emilie Pouget, Matthias Pauly, Alberto Naldoni, Miguel Comesaña-Hermo

Abstract readReview
In one paragraph

Review in The journal of physical chemistry. C, Nanomaterials and interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Charlène BrissaudUniversité Paris Cité, CNRS, ITODYS, 75006 Paris, France.
Swareena JainDepartment of Chemistry and NIS Centre, University of Turin, Turin 10125, Italy.
Olivier HenrotteRegional Centre of Advanced Technologies and Materials Department, Czech Advanced Technology and Research Institute, Palacký University Olomouc, Šlechtitelů 27, Olomouc 78371, Czech Republic.ORCID https://orcid.org/0000-0002-7512-3377
Emilie PougetUniversité of Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, F-33600 Pessac, France.ORCID https://orcid.org/0000-0002-3175-6201
Matthias PaulyUniversité de Strasbourg, CNRS, Institut Charles Sadron UPR22, F-67000 Strasbourg, France.ORCID https://orcid.org/0000-0002-7492-0710
Alberto NaldoniDepartment of Chemistry and NIS Centre, University of Turin, Turin 10125, Italy.ORCID https://orcid.org/0000-0001-5932-2125
Miguel Comesaña-HermoUniversité Paris Cité, CNRS, ITODYS, 75006 Paris, France.ORCID https://orcid.org/0000-0001-8471-5510

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The unique optoelectronic features associated with plasmonic nanomaterials in a broad energy range of the electromagnetic spectrum have the potential to overcome the current limitations in the development of heterogeneous photocatalytic systems with enantioselective capabilities. Recent advancements in creating plasmonic structures with strong chiroptical features have already enabled asymmetric recognition of molecular substrates or even polarization-sensitive chemical reactivity under visible and near-infrared irradiation. Nevertheless, important developments need to be achieved to attain real enantioselective reactivity solely driven by plasmons. This Perspective discusses current trends in the formation of chiral plasmonic materials and their application as photocatalysts to achieve stereocontrol in photochemical reactions. We summarize the challenges in this field and offer insight into future opportunities that could enhance the effectiveness of these innovative systems.

Identifiers

PMID40008194
PMCPMC11849436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.